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A pharmacophore model for the inhibition of Tyrosine Kinase is established that could serve as a
guide for the rational design of high potent and selective inhibitors. Recently, quantitative structure-activ-
ity relationships for 4-anilinoquinazoline class of inhibitors to inhibit EGFR autophosphorylation are in
great demand. We have developed a quantitatively predictive chemical function-based pharmacophore
model by using Discovery Studio 2.1 software. The optimal hypothesis consists of four features: three hy-
drophobic (HYD), and one hydrogen bond donor (HBD) functions. The input for HypoGen was a training
set of 16 compounds exhibiting IC50 values ranging between 0.025 nM and 12000 nM, and having the out-
put borne significant conventional coefficient of 0.97. To further validate our design rationale, pro-
tein-ligand docking software was used to elucidate the intra-molecular interactions. Therefore, the estab-
lished pharmacophore model could help to a better understanding on how the substituents might influence
the activity and afford important information for both ligand-based and structure-based drug designs.
Keywords: Pharmacophore model; Tyrosine kinase; Quantitative structure-activity relationship;
4-Anilinoquinazoline; EGFR; HypoGen.
INTRODUCTION
The protein phosphorylation is a critical mechanism
for regulating protein function in many cell regulatory pro-
cesses.1 Recently, the growth factor signaling pathways are
the main focus of research for the novel cancer chemother-
apy (e.g. breast, lung, colon, and prostate) because of their
fundamental role in regulating key cellular functions which
include cell proliferation, differentiation, metastasis and
survival.2-4 An important mediator of growth factor signal-
ing pathways is the epidermal growth factor receptor
(EGFR). It has been illustrated that small molecules can se-
lectively inhibit the EGFR, and they have a great therapeu-
tic potential in the treatment of malignant and nonmalig-
nant epithelial diseases.
Of several candidate compounds synthesized and
tested, gefitinib (1) was the first EGFR-tyrosine kinase in-
hibitor being approved by US FDA (Food and Drug Ad-
ministration) for the treatment of non-small cell lung can-
cer, and later erlotinib (2), which belongs to same class, and
was used following a prior chemotherapeutic intervention.
In 2007, Lapatinib (3) (Fig. 1) was approved by US FDA to
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Fig. 1. EGFR receptor tyrosine kinase inhibitors in
clinical use.
be used for the clinical trial of breast cancer.5 These agents
belong to the 4-anilinoquinazoline class and the key fea-
tures between the receptor have been revealed. Over the
years, compounds belonging to 4-anilinoquinazoline fam-
ily are reported to be useful as an analgesic and anti-inflam-
matory agent and used in the treatment of cancer. A major
step forwarded in the development of EGFR-targeted drugs
was the discovery of the high inhibitory ability of the
4-[(3-bromophenyl) amino]-quinazoline.6 Nowadays, a
number of reports have been presented that a broad class of
4-anilinoquinazolines are potent and highly selective in-
hibitors of EGF-R phosphorylation, resulting from the
competitive binding at the ATP (Adenosine triphosphate)
site. Since the 4-anilinoquinazoline class of inhibitors has
been discovered to be effective, there is a great demand to
employ the distinctive structure-activity relationship
(SAR) models for a broad class of 4-anilino quinazolines to
investigate their abilities to inhibit EGFR autophos-
phorylation.7,8
Computer-assisted drug design (CADD) represents
the more recent applications of computers as tools in the
drug design process. The success of CADD should depend
upon the amount of information that is available about the
ligand and receptor.9 Based on the information that is avail-
able, one can apply either ligand-based or receptor-based
molecular design methods to find interesting lead mole-
cules quickly. The results can be used to predict biological
activities of untested molecules, propose compounds for
synthesis, validate models of receptor binding sites, and
optimize pharmacokinetic properties of compounds. The
ligand-based approach is applicable when the structure of
the receptor is unknown.When a series of compounds have
been identified that can exert the activity of interest, and
the quantitative structure-activity relationships (QSAR)
would become an alternative powerful theoretical tool for
the description and prediction of properties of complex
molecular systems in different environments.10-13
The ultimate goal of CADD is to determine interest-
ing lead molecules which are worth for further drug re-
search and synthesis by the related laboratory. The factors
which affect the protein-ligand interactions can be charac-
terized by using different QSAR methods or molecular
docking programs.14-18 Pharmacophore modeling is one of
the best 3D-QSAR methods that has been widely used for
generating the chemical features of relative com-
pounds.1921 The method based on 3D structural informa-
tion of molecules, and has been successfully applied to the
drug discovery. For the numerous therapeutically relevant
drug targets with undetermined active site geometries,
pharmacophore modeling has shown to provide an effec-
tive mechanism for virtual screening. In this study,
pharmacophore methodologies are used to establish a cor-
relation between chemical structure and specific biological
activity, the method has been demonstrated as an effective
tool in discovering novel lead compounds.
The purpose of the present work is to establish a
pharmacophore model for the inhibition of Tyrosine
Kinase that could serve as a guide for the rational design of
high potent and selective inhibitors. We focus on the con-
cept of 3D pharmacophores in the context of similarity as-
sessments. A pharmacophore is based on the concept that
specific interactions are observed in the drug and receptor
interactions. In order to rapidly identify the new potential
drugs, it is expected that the established pharmacophore
models are able to correctly elucidate the QSAR of the
tyrosine kinase inhibitors.
MATERIALS AND METHODS
Biological data
The parent compound of Tyrosine Kinase inhibitor
“4-anilinequinazoline” contains quinazoline and aniline
segments (Fig. 2). According to the geometrical analysis,
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Fig. 2. Structure of: (a) 4-anilinequinazoline; (b)
quinazoline; (c) aniline.
quinazoline is made up of two fused six-membered aro-
matic rings; a nitrogen atom connects two electron-rich
groups through two rotatable N-C single bonds. The dihed-
ral angle between the aniline and quinazoline should be
treated with caution. Table 1 shows the chemical structures
of 4-anilinequinazoline derivatives. Medicinally, quinazo-
line-like compounds could be used in various areas espe-
cial in anti-malarial agent and cancer treatment.22 The tyro-
sine kinase activities of the epidermal growth factor recep-
tor which are represented as IC50 in nM, were obtained
from the literature data.6 All the initial inhibition activities
were divided into five levels, and three compounds were
selected from each level to perform the pre-analysis. The
compounds of training and test sets were selected by con-
sidering the fact that test set compounds represent a range
of biological activity and chemical classes similar to that of
the training sets. The selection of a suitable training set is
critical for the quality of pharmacophore models as gener-
ated automatically. To ensure the statistic relevance of the
calculated model, the training set should contain a set of di-
verse compounds and their activity data. These should
spread over 4-5 orders of magnitude equally and are origi-
nated from the comparable binding assays. Each selected
compound should add new information to the model while
avoiding redundancy and bias both in terms of structural
features and activity range.19 In Table 1, all of the training
set compounds are presented as the 2D chemical structures,
the most potent inhibitor shows an IC50 of 0.025 nM and
exhibits the least value of 12,000. Due to the pharmaco-
phore modeling needed, the most active compounds should
provide information on the most critical feature. Thus, on
the basis of the above criteria, 16 compounds for the
training set and 9 compounds for the test set were selected.
Pharmacophore modeling
A pharmacophore is defined as the 3D structural fea-
tures that illustrate how a ligand molecule can interact with
a target receptor in a specific binding site. When the asset
of active ligands is available, it is possible to compute their
shares of pharmacophore.20,21 In particular, pharmacophore
model in Discovery Studio 2.1 is generally referred to as a
‘hypothesis’ which consists of a collection of features nec-
essary for the biological activity of the ligands oriented in
3D space. In order to generate a pharmacophore, all mole-
cules (both training and test sets) should be built and mini-
mized within the Discovery Studio 2.1 software.15 Confor-
mation models for all of the molecules were generated by
using the CHARMM force field parameters and a con-
straint of 20 kcal/mol energy thresholds above the global
energy minimum.23 Discovery Studio 2.1 selects conform-
ers using the Poling algorithm, that penalizes any newly
generated conformer which is too close to an already
formed conformer in the set.24 This method ensures maxi-
mum coverage in conformational space. All other parame-
ters were set to the default settings.
The resulting hypotheses are specified as several de-
fault feature types (e.g. hydrogen bond acceptor, hydrogen
bond donor, hydrophobic, ring aromatic, negative/positive
ionizable) located at the well-defined positions (location
constraints). These are surrounded by certain spatial toler-
ance spheres, designating the area in space to be occupied
by the corresponding chemical functions of the matched
molecule. Each of the features is assigned a certain weight
that is proportional to its relative contribution to the biolog-
ical activity. Hydrogen bond acceptors/donors, and aro-
matic rings include an additional vector, defining the direc-
tion of the interaction. The results of the hypotheses in-
clude different statistical values calculated during the
model generation, and the best model should be selected on
the basis of the lowest total cost, rms values and high corre-
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Table 1. Structure of 4-anilinoquinazoline class of inhibitors and
relative IC50
1-15 16
No. R1 R2 X IC50 (nM)
1 H H CF3 577.000
2 NO2 H H 5000.000
3 NO2 H Br 900.000
4 H OMe Br 10.000
5 H NH2 H 100.000
6 H NH2 F 2.000
7 H NH2 I 0.350
8 H NO2 H 12000.000
9 H NO2 F 6100.000
10 OMe OMe Br 0.025
11 OMe OMe I 0.890
12 NMe2 H Br 84.000
13 H OH Br 4.7000
14 H NHAc Br 40.000
15 H NHMe Br 7.000
16 5,6-diOMe 1367.000
lation of the 3D arrangement of features with their corre-
sponding pharmacological activities in a given set of train-
ing compounds.
RESULTS AND DISCUSSION
There are several methods for generating 3D QSAR
models. Several 3D QSAR studies of quinazoline type
EGF-R inhibitors have been reported.12,25 In one example,
the steric and electrostatic fields were computed, and corre-
lated with the activity (e.g. CoMFA, CoMSIA).26 The re-
sults for the ligand-based design indicated that the elec-
tron-withdrawing lipophilic substituents on the 3’-position
of the aniline are favorable, and electron-donating groups
at the 6- and 7-postion of the quinazoline are preferred.
However, CoMFA or CoMSIA is incapable of de-
scribing appropriately all binding forces, because the
mothod is based only on standard steric and electrostatic
molecular fields to model receptor-ligand interactions. In
Discovery Studio, 3D QSAR models are generated and
based on how well a series of ligands fit in a pharmaco-
phore. The better a ligand fits a pharmacophore (e.g. the
more features that map and the closer they are to the feature
centroids), the more active it is predicted to be. To assess
the significance of the receptor-ligand interaction, we pre-
sented an evaluation of the cross-validation for the
pharmacophore results and used LibDock protocol for the
docking of ligands into the binding pocket of EGFR.27
Pharmacophore Generation & Assessment
3D QSARs differ from typical QSAR methods in that
the descriptors are derived from ligand alignments or how
well ligands fit a pharmacophore, rather than the molecular
features. Often, the descriptors are concerned with the
overall molecule instead of a single substituent. In Discov-
ery Studio, 3D QSAR models are generated and based on
howwell a series of ligands fit a pharmacophore. The better
a ligand fits a pharmacophore (i.e., the more features that
map and the closer they are to the feature centroids), the
more active it is predicted to be.
Since the Pharmacophore Generation protocol can
only generate a maximum of five features for a hypothesis.
An initial analysis of the “show function mapping” tools
revealed that hydrogen bond acceptor (HBA), hydrogen
bond donor (HBD), hydrophobic (HYD), and ring aro-
matic (RA) features could effectively map all the critical
chemical/structural features of all the training set mole-
cules. Therefore, these features were used to generate 10
pharmacophore hypotheses from the training set, using a
default uncertainty value of 3. The uncertainty value repre-
sents a ratio range of uncertainty in the activity value based
on the expected statistical irregularities of biological data
collected.
The quantitative models were generated for the six-
teen compounds in the training set (compound 1-16, Table
1). Table 2 lists the top 10 hypothesis generated by
HypoRefine algorithm together with their statistical pa-
rameters. As shown in Fig. 3, the best hypothesis Hypo1
contains three features, including one hydrogen-bond ac-
ceptor (A), and three hydrophobic features (including
aliphatic and aromatic). The main difference between
Hypo1 and Hypo2 was the addition of excluded volume.
Although Hypo2 has slight improvement in the rms value,
Hypo1 comprehends two excluded volume (E) which ex-
hibit the significant meaning of actual ligand-protein inter-
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Table 2. Results obtained from pharmacophore hypothesis generation using the training set
moleculesa
Hypo number Total cost rms Correlation Featuresb
1 73.81 0.98 0.95 HBD, HYD, aliHYD, aroHYD
2 74.11 0.97 0.96 HBD, HYD, aliHYD, HYD
3 74.30 1.01 0.95 HBD, HYD, aroHYD, HYD
4 75.49 0.93 0.96 HBD, HYD, HYD, HYD
5 82.00 1.41 0.90 HBD, HYD, aliHYD HYD, R A
6 82.92 1.44 0.90 HBD, HYD, alipHYD, aroHYD, R A
7 89.90 1.76 0.84 HBD, HYD, alipHYD, alipHYD, aroHYD
8 95.36 2.05 0.78 HBD, HYD, R A
9 95.89 2.22 0.71 HYD, HYD, HYD, HYD
10 96.24 2.21 0.71 HBD, HYD, HYD, HYD, HYD
a Null cost = 123.97 and Fixed cost = 58.67. All costs are in units of bits.
b HBD (hydrogen bond donor), HYD (hydrophobic, ali = aliphatic, aro = aromatic) and RA (ring aromatic).
actions. Besides, Hypo1 was characterized by the good cor-
relation coefficient (0.95), the lowest total cost value
(73.81), and the acceptable rms (0.98).
Validation of Pharmacophores
Ideally, a good pharmacophore model should not only
be able to predict the activities of the training set com-
pounds accurately, but also can predict the activities of ex-
ternal compounds of test set.28 To further validate our de-
sign rationale, cross-validation methods were used for as-
sessing the performance of the generated pharmacophore
models. For the use of test set method, nine compounds
with different bioactivities represented as (-log IC50) and
structures were selected to form a test set. Discovery Studio
2.1/Ligand Pharmacophore Mapping protocol was used
with Hypo 1 as pharmacophore model to screen the de-
signed database. All of the test set compounds were pre-
pared by using the same method as that for the training set,
and the model analysis has resulted in the unique model
with a cross-validated coefficient of 0.762 (Fig. 4). Further
attempts were also made to classify the real screening re-
sults to the active and inactive compounds by applying the
pharmacophore model. For this purpose, the activity values
of the training set compounds were classified into three cat-
egories: highly active (IC50  50 nM, +++), moderately ac-
tive (50 < nM IC50  1000 nM, ++), and low active (IC50 >
1000 nM, +). Table 3 shows the predicted and experimental
inhibitory activities of these 16 molecules in the training
set. This classification scheme is shown to be more conse-
quential than the actual prediction values.
Docking Study
Protein-ligand docking software is widely used to
promote the drug design that has the potential to identify
the promising lead compounds at an early stage of the drug
discovery pipeline.2931 LibDock is based on matching the
polar and apolar binding site features of the protein-ligand
complex, and this algorithm was developed by Diller and
Merz.32 The algorithm uses protein site features referred to
as HotSpots which consist of polar and apolar types. Polar
Hotspot is preferred by a polar ligand atom (e.g. a hydrogen
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Fig. 4. Plot of the correlation between the experimen-
tal and predicted activities (by using Hypo1)
for the (a) Training set and (b) Test set com-
pounds.
Fig. 3. HipHop model generated by compounds (1-16)
in the training set (Hypo1).
bond donor or acceptor) and an apolar HotSpot is preferred
by an apolar atom (e.g. a carbon atom). The receptor
HotSpot file was calculated prior to the docking procedure.
The following docking study was carried out by LibDock
within Discovery Studio 2.1 package (Accelrys, San
Diego, U.S.A.), and the Dreiding force field was used for
all calculations. The docking and subsequent scoring were
performed by using default parameters, where the X-ray
structure of EGFR-R in complex with a POX inhibitor were
obtained from the Brookhaven Protein Data Bank (PDB
code: 3BEL1). The binding site of the bound ligand (POX,
4-amino-6-{[1-(3-fluorobenzyl)-1H-indazol- 5-yl]amino}-
pyrimidine-5-carbaldehyde O-(2- methoxyethyl)oxime)
was identified as the active site, and the solvent molecules
far away the active site were removed (Fig. 5).
The binding modes of the quinazoline type inhibitors
at the ATP binding site of EGF-R have been reported by
several groups.1 The nitrogen atom connects both aniline
and quinazoline groups, and the direction of the hydrogen
bond acceptor is vital for the inhibitory activity. The SAR
at the oxime side chain (R2 group) has been reported to
have a negative effect against activity.25 In this work, we
focus our attention on the surrounding of each pharma-
cophore features. The results show that compounds with
hydrophobic substituents at 6 and 7 positions of the
quinazoline are more potent in the experimental assay. This
observation is also in agreement with the pharmacophore
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Table 4. Results of LibDock docking score and corresponding
experimental value
Compoud
No
Structure
LibDock
docking score
Experimenta
l IC50 (nm)
T1 123.403 0.240
T2 120.193 0.170
T3 113.551 0.006
T4 109.456 3.800
T5 100.118 23.000
T6 98.265 12000.000
Table 3. Experimental and predicted activities (using Hypo1) of the training set compounds
Compoud No. Experimental IC50 (nm) Predicted IC50 (nm) Error
a Fit valueb Experimental scalec Predicted scalec
1 0.025 0.046 +1.84 10.43 +++ +++
2 0.890 0.726 -1.23 10.42 +++ +++
3 3.300 2.993 -1.10 8.83 +++ +++
4 0.350 3.784 +10.81 8.67 +++ +++
5 4.700 5.869 +1.25 8.47 +++ +++
6 10.000 8.614 -1.16 8.29 +++ +++
7 40.000 9.469 -4.22 8.25 +++ +++
8 7.000 10.440 +1.49 8.21 +++ +++
9 84.000 44.197 -1.90 7.99 ++ +++
10 100.000 51.566 -1.94 7.08 ++ ++
11 540.000 302.742 -1.78 6.95 ++ ++
12 1000.000 406.343 -2.43 6.86 ++ ++
13 1367.000 2332.250 +1.71 6.68 + +
14 900.000 3569.360 +3.97 6.60 ++ +
15 6000.000 5482.320 -1.09 5.84 + +
16 12000.000 6023.580 -1.99 5.77 + +
a A ratio between the experimental and predicted activities. A positive value indicates that the predicted IC50 is lower than the
experimental IC50.
b Fit value indicates how well the features in the hypothesis overlap the chemical features in the compound.
c Activity scale: +++, IC50  50 nM (highly active); ++, 50 nM < IC50  1000 nM (moderately active); +, IC50 > 1000 nM (low
active).
model. In Fig. 6, the substituent at 3’-position of aniline oc-
cupies a pocket formed by the side chains of Met766,
Leu777, Thr790, Thr854, and Phe856 (Fig. 6a, 6b). Elec-
tron-withdrawing lipophilic substituents on the 3-position
of the aniline are favorable, especially the chlorine and bro-
mine groups give the optimal effect. Both the steric effect
and intra-molecular hydrogen bond favor the inhibitory ac-
tivity, such phenomenon is revealed in Fig. 5. The replace-
ment by trifluoromethyl group may further enhance the hy-
drogen bond formation among the residues. Moreover, the
electron-donating groups at R1 position of the quinazoline
are preferred.
Molecular surface comparison
The study of molecular surface is an important analy-
sis of geometry, it can be used for the exploration of a pro-
tein folding, docking, and interactions between proteins.
Various physical chemical properties can be mapped onto
the molecular surface. To further validate our design ratio-
nale, we compared the shape of the highest activity com-
pound T1 and POX (Fig. 7a, 7b), and the higher score com-
pounds were shown to have similar orientation lying on the
active site position. According to the docking results, three
compounds (T1, T2, and T3) exhibited high scores that
have the same backbone near the free NH linker, and the
torsion angle defined by aniline and pyrimidine is around
100 degree (Fig. 7c). The hydrophobicity of aliphatic fea-
ture suggests that alkyl chain at the C-7 position is an im-
portant hint. This assumption agrees well with the structure
surface of POX.
The results from the above structural analysis of pro-
tein-ligand relationship provide the explaination of the
binding modes which were shown to fit the pharmacophore
model and the docking results. The amino modes around
anilino group form extra intramolecular hydrogen bonds,
and the overall molecular surface should fit the molecule
shape as well as the POX inhibitor.
CONCLUSIONS
A pharmacophore modeling, containing HipHop and
HypoRefine modules within Discovery Studio 2.1 software
package, was used to elucidate the structure-activity rela-
tionship of tyrosine kinase inhibitors. The pharmacophore
model Hypo1 was shown to give the best quantitative re-
sults with a high correlation coefficient (0.968), and pos-
sess the best predictive power (cross-validation correlation
coefficient of 0.762). The results on docking scores pro-
vide information on the geometry of the binding site cavity
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Fig. 5. Stereoview for comparative binding affinities
of POX (yellow, ball and stick).
Fig. 6. (a) Complexed structure of docking result:
compound T1 and protein residues are colored
as yellow and green, respectively. (b) Molecu-
lar surface is created by POX inhibitor.
and the relative substituents of various properties in differ-
ent site pockets for each of the substrates considered. Fi-
nally, the molecular surface structure of quinazoline type
inhibitor with EGFR together with the pharmacophore
mapping from the software offer well interpretation on the
structure activities of the inhibitors and afford us important
information for protein-ligand relationship.
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